Research programme: NCAM agonists - ENKAM Pharmaceuticals

Drug Profile

Research programme: NCAM agonists - ENKAM Pharmaceuticals

Alternative Names: Dennexin; Fibroblast growth factor (FGF) receptor agonists - ENKAM; NCAM mimetic peptides; NCAM mimetics; P2; P2-peptide; Plannexin; TBI therapeutics - ENKAM; Traumatic brain injury therapeutics - ENKAM

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Fibroblast growth factor receptor agonists; Neural cell adhesion molecule agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain injuries

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain injuries in Denmark (SC, Injection)
  • 27 May 2011 Preclinical development is ongoing in Denmark
  • 07 Nov 2007 Pharmacodynamics data from a preclinical trial presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top